rden3delta30
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 16, 2016 (NCT02684383)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rden3delta30
- rden3δ30
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03416036 | Phase 1 | Nov 28, 2017 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02873260 | Phase 1 | Aug 16, 2016 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02684383 | Phase 1 | Feb 16, 2016 | National Institute of Allergy and Infectious Diseases (NIAID), University of Vermont |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| University of Vermont | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1